COMP <GO>
EHC vs JNJ // RSI-14 & 200D SMA MOMENTUM
Encompass Health Corporation (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: EHC 7
— JNJ 8
▲ RSI-14 & 200D SMA MOMENTUM LEADER: EHC
LAST: $135.90 (+3.35%) • MKT CAP: $12.97B
rsi-technicals
69.2
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
rsi-technicals
60.4
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EHC VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EHC | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 67.90% | -26.90 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 13.80% | 25.50% | -11.70 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 15.8x | 18.5x | -2.70 | EHC | /valuation <GO> |
| Free Cash Flow Yield | 2.92% | 2.97% | -0.05 | JNJ | /fcf-yield <GO> |
| Operating Margin | 11.60% | 34.70% | -23.10 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 9.50% | 28.50% | -19.00 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 10.50% | 6.00% | +4.50 | EHC | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.55% | 0.00% | +0.55 | EHC | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.47 | 5.59 | -2.12 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | EHC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.60% | 7.20% | -0.60 | EHC | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 69.2 | 60.4 | +8.88 | EHC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.90 | 1.08 | -0.18 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 21.3x | 23.0x | -1.70 | EHC | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $12.97B | $662.49B | -$649.52B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EHC REV | JNJ REV | EHC GROSS % | JNJ GROSS % | EHC FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.94B | $94.19B | 44.0% | 67.9% | $367.1M | $19.70B |
| FY 2024 | $5.37B | $88.82B | 44.0% | 69.1% | $268.6M | $19.84B |
| FY 2023 | $4.80B | $85.16B | 44.0% | 44.0% | $178.2M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EHC // BETA 0.90
JNJ // BETA 1.08